- Caliper Addresses Key Bottlenecks in Quality by Design Initiative for Protein Therapeutics -
HOPKINTON, Mass., June 29 Caliper Life Sciences, Inc. , a leading provider of tools and services for drug discovery and life sciences research, today launched the Staccato Protein Workstation to specifically address bottlenecks in the characterization of biological therapeutics and biogenerics.
With a goal of assuring the quality of therapeutic proteins and monoclonal antibodies, as well as creating mechanisms for approval of follow-on protein products (biosimilars), the FDA has encouraged the industry to submit biological new drug applications that include quality by design (QbD) parameters. QbD approaches require multivariate experimentation techniques that generate large numbers of samples and create bottlenecks in sample preparation and analysis.
“The Staccato Protein Workstation is designed to address the sample preparation and analysis bottlenecks caused by increased sample requirements of QbD approaches, and is also directly applicable to research groups performing protein expression optimization, clone selection, and other high throughput techniques,” said Kevin Keras, Business Unit Manager, ACES, Caliper Life Sciences. “Caliper has worked with several of our LabChip GXII customers, including Dow and Amgen, to develop custom automation solutions to integrate sample preparation and analysis steps. Recognizing the broader need for this workflow automation, Caliper has created the Staccato Protein Workstation as an off-the-shelf solution.”
The Staccato Protein Workstation, developed by Caliper’s Automation, Consulting, Engineering, and Services (ACES) group, incorporates the Sciclone ALH 3000 for automated liquid handling, Twister II for microplate handling, LabChip GXII for microfluidic protein characterization, and various accessories for complete workflow automation. The LabChip GXII is Caliper’s high throughput system for analyzing protein size, concentration, and purity and serves as a replacement for traditional polyacrylamide gel electrophoresis (PAGE). Since its launch in July, 2008, the LabChip GXII platform has been widely adopted by high throughput protein analysis laboratories including companies such as Eli Lilly, GSK Biologics, Merck and Novartis; government and academic institutions such as Howard Hughes Medical Institute, Karlshrue Institute of Technology, National Cancer Institute, Sandia National Laboratories, and University of Queensland; and biotechnology companies such as Amgen, ICx Biosystems, and XcellereX.
For additional information on Caliper’s research tools for sample preparation and quality control of biologicals, please visit http://www.caliperls.com/products/aces/staccato-protein-workstations.htm
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
Caliper, Sciclone, Staccato, Twister, and LabChip are registered trademarks, and ACES is a trademark, of Caliper Life Sciences, Inc.
CONTACT: Stacey Holifield or Kristin Villiotte, both of Schwartz
Communications for Caliper Life Sciences, Inc., +1-781-684-0770,
caliper@schwartz-pr.com
Web site: http://www.caliperls.com/
